Wells Fargo raised the firm’s price target on Oric Pharmaceuticals (ORIC) to $25 from $19 and keeps an Overweight rating on the shares. While enozertinib has largely taken a back seat to ORIC-944, its data presented at ESMO Asia is intriguing and Wells thinks enough for investors to start assigning more credit. The firm believes shares should trade up.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Buy Rating for Oric Pharmaceuticals: Enozertinib’s Promising Efficacy and Strategic Value
- Oric Pharmaceuticals presents data from Phase 1b trial of enozertinib
- Promising Clinical Data and Market Potential Drive Buy Rating for Oric Pharmaceuticals’ Enozertinib
- Oric Pharmaceuticals presents data from enozertinib trial at ESMO Asia
- Oric Pharmaceuticals initiated as Early Stage Biotech at Goldman Sachs